Top

Published in:

Open Access 01-12-2024 | Prostate Cancer | Research

HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis

Authors: Lihong Yang, Yong Ruan, Houqiang Xu

Published in: BMC Cancer | Issue 1/2024

Abstract

In recent years, there has been an increase in the incidence and mortality rates of prostate cancer (PCa). However, the specific molecular mechanisms underlying its occurrence and development remain unclear, necessitating the identification of new therapeutic targets. Through bioinformatics analysis, we discovered a previously unstudied differential gene called HIST3H2A in prostate cancer. Our study revealed that HIST3H2A is highly expressed in PCa tissues, as confirmed by analysis of both the GEO and UALCAN databases. Further analysis using the KEGG database demonstrated that HIST3H2A regulates the pathway of programmed necroptosis in cells. Additionally, we observed significant up-regulation of HIST3H2A in PCa tissues and cell lines. HIST3H2A was found to regulate cell proliferation, migration, invasion, and the epithelial-mesenchymal transition (EMT) process in tumors. Notably, HIST3H2A’s role in regulating programmed necroptosis in prostate cancer cells differs from its role in apoptosis. In vitro and in vivo experiments collectively support the key role of HIST3H2A in promoting the development of prostate cancer, highlighting its potential as a therapeutic target for patients with PCa.

Available only for authorised users

Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23. https://doi.org/10.1038/nrclinonc.2014.68.CrossRefPubMedPubMedCentral

Schatten H. Brief overview of prostate Cancer statistics, Grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14. https://doi.org/10.1007/978-3-319-95693-0_1.CrossRefPubMed

Vietri MT, D’Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM. Hereditary prostate Cancer: genes related, Target Therapy and Prevention. Int J Mol Sci. 2021;22(7):3753. https://doi.org/10.3390/ijms22073753.CrossRefPubMedPubMedCentral

D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92. https://doi.org/10.1002/cbin.11137.CrossRefPubMed

Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15(1):174. https://doi.org/10.1186/s13045-022-01392-3.CrossRefPubMedPubMedCentral

Li M, Wang ZW, Fang LJ, Cheng SQ, Wang X, Liu NF. Programmed cell death in atherosclerosis and vascular calcification. Cell Death Dis. 2022;13(5):467. https://doi.org/10.1038/s41419-022-04923-5.CrossRefPubMedPubMedCentral

Green DR, The Coming Decade of Cell Death Research. Five Riddles Cell. 2019;177(5):1094–107. https://doi.org/10.1016/j.cell.2019.04.024.CrossRefPubMed

Hahn M, Dambacher S, Schotta G. Heterochromatin dysregulation in human diseases. J Appl Physiol (1985). 2010;109(1):232–42. https://doi.org/10.1152/japplphysiol.00053.2010.CrossRefPubMed

Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29(5):258–89. https://doi.org/10.1016/j.mam.2008.08.001.CrossRefPubMedPubMedCentral

10.

Rosenfeld E, Ganguly A, De Leon DD. Congenital hyperinsulinism disorders: genetic and clinical characteristics. Am J Med Genet C Semin Med Genet. 2019;181(4):682–92. https://doi.org/10.1002/ajmg.c.31737.CrossRefPubMedPubMedCentral

11.

Schuschel K, Helwig M, Hüttelmaier S, Heckl D, Klusmann JH, Hoell JI. RNA-Binding proteins in Acute Leukemias. Int J Mol Sci. 2020;21(10):3409. https://doi.org/10.3390/ijms21103409.CrossRefPubMedPubMedCentral

12.

Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, Qi D, Lin C, Tong R, Wang Y. RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (review). Int J Mol Med. 2019;44(3):771–86. https://doi.org/10.3892/ijmm.2019.4244.CrossRefPubMedPubMedCentral

13.

Guo C, Fu R, Zhou M, Wang S, Huang Y, Hu H, Zhao J, Gaskin F, Yang N, Fu SM. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J Autoimmun. 2019;103:102286. https://doi.org/10.1016/j.jaut.2019.05.014.CrossRefPubMedPubMedCentral

14.

Chen D, Gregory AD, Li X, Wei J, Burton CL, Gibson G, Scott SJ, St Croix CM, Zhang Y, Shapiro SD. RIP3-dependent necroptosis contributes to the pathogenesis of chronic obstructive pulmonary disease. JCI Insight. 2021;6(12):e144689. https://doi.org/10.1172/jci.insight.144689.CrossRefPubMedPubMedCentral

15.

Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1–2):213–27. https://doi.org/10.1016/j.cell.2011.11.031.CrossRefPubMed

16.

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, Liu C. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100. https://doi.org/10.1186/s12943-019-1029-8.CrossRefPubMedPubMedCentral

17.

Liu S, Joshi K, Denning MF, Zhang J. RIPK3 signaling and its role in the pathogenesis of cancers. Cell Mol Life Sci. 2021;78(23):7199–217. https://doi.org/10.1007/s00018-021-03947-y.CrossRefPubMedPubMedCentral

18.

Wang Y, Zhao M, He S, Luo Y, Zhao Y, Cheng J, Gong Y, Xie J, Wang Y, Hu B, Tian L, Liu X, Li C, Huang Q. Necroptosis regulates tumor repopulation after radiotherapy via RIP1/RIP3/MLKL/JNK/IL8 pathway. J Exp Clin Cancer Res. 2019;38(1):461. https://doi.org/10.1186/s13046-019-1423-5.CrossRefPubMedPubMedCentral

19.

Liu C, Chen Y, Cui W, Cao Y, Zhao L, Wang H, Liu X, Fan S, Huang K, Tong A, Zhou L. Inhibition of neuronal necroptosis mediated by RIP1/RIP3/MLKL provides neuroprotective effects on kaolin-induced hydrocephalus in mice. Cell Prolif. 2021;54(9):e13108. https://doi.org/10.1111/cpr.13108.CrossRefPubMedPubMedCentral

20.

Xue H, Shi H, Zhang F, Li H, Li C, Han Q. RIP3 contributes to Cardiac Hypertrophy by influencing MLKL-Mediated calcium influx. Oxid Med Cell Longev. 2022;2022:5490553. https://doi.org/10.1155/2022/5490553.CrossRefPubMedPubMedCentral

21.

Cutter AR, Hayes JJ. A brief review of nucleosome structure. FEBS Lett. 2015;589(20 Pt A):2914-22. https://doi.org/10.1016/j.febslet.2015.05.016.

22.

Kale S, Goncearenco A, Markov Y, Landsman D, Panchenko AR. Molecular recognition of nucleosomes by binding partners. Curr Opin Struct Biol. 2019;56:164–70. https://doi.org/10.1016/j.sbi.2019.03.010.CrossRefPubMedPubMedCentral

23.

Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703–8. https://doi.org/10.1038/nrm3890.CrossRefPubMed

24.

Wang X, Bai L, Bryant GO, Ptashne M. Nucleosomes and the accessibility problem. Trends Genet. 2011;27(12):487–92. https://doi.org/10.1016/j.tig.2011.09.001.CrossRefPubMed

25.

Feng Y, Endo M, Sugiyama H. Nucleosomes and epigenetics from a Chemical Perspective. ChemBioChem. 2021;22(4):595–612. https://doi.org/10.1002/cbic.202000332.CrossRefPubMed

26.

Huertas J, Cojocaru V. Breaths, twists, and turns of atomistic nucleosomes. J Mol Biol. 2021;433(6):166744. https://doi.org/10.1016/j.jmb.2020.166744.CrossRefPubMed

27.

Fedyuk V, Erez N, Furth N, Beresh O, Andreishcheva E, Shinde A, Jones D, Zakai BB, Mavor Y, Peretz T, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Maoz M, Zick A, Ron G, Shema E. Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics. Nat Biotechnol. 2023;41(2):212–21. https://doi.org/10.1038/s41587-022-01447-3.CrossRefPubMed

28.

He S, Wu Z, Tian Y, Yu Z, Yu J, Wang X, Li J, Liu B, Xu Y. Structure of nucleosome-bound human BAF complex. Science. 2020;367(6480):875–81. https://doi.org/10.1126/science.aaz9761.CrossRefPubMed

29.

Giaimo BD, Ferrante F, Herchenröther A, Hake SB, Borggrefe T. The histone variant H2A.Z in gene regulation. Epigenetics Chromatin. 2019;12(1):37. https://doi.org/10.1186/s13072-019-0274-9.CrossRefPubMedPubMedCentral

30.

Dryhurst D, Ausió J. Histone H2A.Z deregulation in prostate cancer. Cause or effect? Cancer Metastasis Rev. 2014;33(2–3):429–39. https://doi.org/10.1007/s10555-013-9486-9.CrossRefPubMedPubMedCentral

31.

Rangasamy D. Histone variant H2A.Z can serve as a new target for breast cancer therapy. Curr Med Chem. 2010;17(28):3155–61. https://doi.org/10.2174/092986710792231941.CrossRefPubMed

32.

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T. DS-8201a, A Novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a Promising Antitumor Efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108. https://doi.org/10.1158/1078-0432.CCR-15-2822.CrossRefPubMed

33.

Ge Y, Liu BL, Cui JP, Li SQ. Livin promotes colon cancer progression by regulation of H2A.XY39ph via JMJD6. Life Sci. 2019;234:116788. https://doi.org/10.1016/j.lfs.2019.116788.CrossRefPubMed

34.

Guo ZF, Kong FL. Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer. Oncol Lett. 2021;21(3):187. https://doi.org/10.3892/ol.2021.12448.CrossRefPubMedPubMedCentral

35.

Gao X, Bao H, Liu L, Zhu W, Zhang L, Yue L. Systematic analysis of lysine acetylome and succinylome reveals the correlation between modification of H2A.X complexes and DNA damage response in breast cancer. Oncol Rep. 2020;43(6):1819–30. https://doi.org/10.3892/or.2020.7554. Epub 2020 Mar 19.CrossRefPubMedPubMedCentral

36.

Liu Y, Long YH, Wang SQ, Zhang YY, Li YF, Mi JS, Yu CH, Li DY, Zhang JH, Zhang XJ. JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. Oncogene. 2019;38(7):980–97. https://doi.org/10.1038/s41388-018-0466-y.CrossRefPubMed

37.

Miyake K, Takano N, Kazama H, Kikuchi H, Hiramoto M, Tsukahara K, Miyazawa K. Ricolinostat enhances adavosertib–induced mitotic catastrophe in TP53–mutated head and neck squamous cell carcinoma cells. Int J Oncol. 2022;60(5):54. https://doi.org/10.3892/ijo.2022.5344.CrossRefPubMedPubMedCentral

38.

Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl. 2006;70457–65. https://doi.org/10.1007/978-3-211-45295-0_69.

39.

Kim JH, Jeon S, Choi HD, Lee JH, Bae JS, Kim N, Kim HG, Kim KB, Kim HR. Exposure to long-term evolution radiofrequency electromagnetic fields decreases neuroblastoma cell proliferation via Akt/mTOR-mediated cellular senescence. J Toxicol Environ Health A. 2021;84(20):846–57. https://doi.org/10.1080/15287394.2021.1944944.CrossRefPubMed

40.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8. https://doi.org/10.1038/nprot.2008.73.CrossRefPubMed

41.

Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, Offermann A, Pantel K, Schuele R, Taubert H, Wach S, Perner S, Werner S, Aigner A. Experimental in vitro, ex vivo and in vivo models in prostate cancer research. Nat Rev Urol. 2023;20(3):158–78. https://doi.org/10.1038/s41585-022-00677-z.CrossRefPubMed

42.

Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate Cancer. Semin Nucl Med. 2016;46(6):484–90. https://doi.org/10.1053/j.semnuclmed.2016.07.002.CrossRefPubMed

43.

Prostate cancer. Nat Rev Dis Primers. 2021;7(1):8. https://doi.org/10.1038/s41572-021-00249-2.CrossRef

44.

Kaiser A, Haskins C, Siddiqui MM, Hussain A, D’Adamo C. The evolving role of diet in prostate cancer risk and progression. Curr Opin Oncol. 2019;31(3):222–9. https://doi.org/10.1097/CCO.0000000000000519.CrossRefPubMedPubMedCentral

45.

Smith ZL, Eggener SE, Murphy AB. African-American prostate Cancer disparities. Curr Urol Rep. 2017;18(10):81. https://doi.org/10.1007/s11934-017-0724-5.CrossRefPubMed

46.

Ghafouri-Fard S, Shabestari FA, Vaezi S, Abak A, Shoorei H, Karimi A, Taheri M, Basiri A. Emerging impact of quercetin in the treatment of prostate cancer. Biomed Pharmacother. 2021;138:111548. https://doi.org/10.1016/j.biopha.2021.111548.CrossRefPubMed

47.

Wilt TJ, Ullman KE, Linskens EJ, MacDonald R, Brasure M, Ester E, Nelson VA, Saha J, Sultan S, Dahm P. Therapies for clinically localized prostate Cancer: a comparative effectiveness review. J Urol. 2021;205(4):967–76. https://doi.org/10.1097/JU.0000000000001578.CrossRefPubMed

48.

Jansen A, Verstrepen KJ. Nucleosome positioning in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2011;75(2):301–20. https://doi.org/10.1128/MMBR.00046-10.CrossRefPubMedPubMedCentral

49.

Andrews AJ, Luger K. Nucleosome structure(s) and stability: variations on a theme. Annu Rev Biophys. 2011;40:99–117. https://doi.org/10.1146/annurev-biophys-042910-155329.CrossRefPubMed

50.

Korber P. Active nucleosome positioning beyond intrinsic biophysics is revealed by in vitro reconstitution. Biochem Soc Trans. 2012;40(2):377–82. https://doi.org/10.1042/BST20110730.CrossRefPubMed

51.

Szerlong HJ, Hansen JC. Nucleosome distribution and linker DNA: connecting nuclear function to dynamic chromatin structure. Biochem Cell Biol. 2011;89(1):24–34. https://doi.org/10.1139/O10-139.CrossRefPubMedPubMedCentral

52.

Wolffe AP, Kurumizaka H. The nucleosome: a powerful regulator of transcription. Prog Nucleic Acid Res Mol Biol. 1998;61:379–422. https://doi.org/10.1016/s0079-6603(08)60832-6.CrossRefPubMed

53.

Schwab DJ, Bruinsma RF, Rudnick J, Widom J. Nucleosome switches. Phys Rev Lett. 2008;100(22):228105. https://doi.org/10.1103/PhysRevLett.100.228105.CrossRefPubMedPubMedCentral

54.

Jiang X, Wen J, Paver E, Wu YH, Sun G, Bullman A, Dahlstrom JE, Tremethick DJ, Soboleva TA. H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma. EMBO Rep. 2021;22(8):e52462. https://doi.org/10.15252/embr.202152462.CrossRefPubMedPubMedCentral

55.

Han S, Cao C, Liu R, Yuan Y, Pan L, Xu M, Hu C, Zhang X, Li M, Zhang X. GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer. Cell Oncol (Dordr). 2022;45(3):429–46. https://doi.org/10.1007/s13402-022-00675-8.CrossRefPubMed

56.

Berta DG, Kuisma H, Välimäki N, Räisänen M, Jäntti M, Pasanen A, Karhu A, Kaukomaa J, Taira A, Cajuso T, Nieminen S, Penttinen RM, Ahonen S, Lehtonen R, Mehine M, Vahteristo P, Jalkanen J, Sahu B, Ravantti J, Mäkinen N, Rajamäki K, Palin K, Taipale J, Heikinheimo O, Bützow R, Kaasinen E, Aaltonen LA. Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. Nature. 2021;596(7872):398–403. https://doi.org/10.1038/s41586-021-03747-1.CrossRefPubMed

57.

Hu X, Wang Z, Kong C, Wang Y, Zhu W, Wang W, Li Y, Wang W, Lu S. Necroptosis: a new target for prevention of osteoporosis. Front Endocrinol (Lausanne). 2022;13:1032614. https://doi.org/10.3389/fendo.2022.1032614.CrossRefPubMed

58.

Seo J, Nam YW, Kim S, Oh DB, Song J. Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators. Exp Mol Med. 2021;53(6):1007–17. https://doi.org/10.1038/s12276-021-00634-7.CrossRefPubMedPubMedCentral

59.

Sarcognato S, Jong IEM, Fabris L, Cadamuro M, Guido M. Necroptosis Cholangiocarcinoma Cells. 2020;9(4):982. https://doi.org/10.3390/cells9040982.CrossRefPubMed

60.

Martens S, Bridelance J, Roelandt R, Vandenabeele P, Takahashi N. MLKL in cancer: more than a necroptosis regulator. Cell Death Differ. 2021;28(6):1757–72. https://doi.org/10.1038/s41418-021-00785-0.CrossRefPubMedPubMedCentral

61.

Lee SA, Chang LC, Jung W, Bowman JW, Kim D, Chen W, Foo SS, Choi YJ, Choi UY, Bowling A, Yoo JS, Jung JU. OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis. Nat Cell Biol. 2023;25(1):92–107. https://doi.org/10.1038/s41556-022-01039-y.CrossRefPubMedPubMedCentral

62.

Verdonck S, Nemegeer J, Vandenabeele P, Maelfait J. Viral manipulation of host cell necroptosis and pyroptosis. Trends Microbiol. 2022;30(6):593–605. https://doi.org/10.1016/j.tim.2021.11.011.CrossRefPubMed

63.

Anosike NL, Adejuwon JF, Emmanuel GE, Adebayo OS, Etti-Balogun H, Nathaniel JN, Omotosho OI, Aschner M, Ijomone OM. Necroptosis in the developing brain: role in neurodevelopmental disorders. Metab Brain Dis. 2023;38(3):831–7. https://doi.org/10.1007/s11011-023-01203-9.CrossRefPubMed

64.

Negroni A, Colantoni E, Cucchiara S, Stronati L. Necroptosis in intestinal inflammation and Cancer: New concepts and therapeutic perspectives. Biomolecules. 2020;10(10):1431. https://doi.org/10.3390/biom10101431.CrossRefPubMedPubMedCentral

Title: HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis
Authors: Lihong Yang
Yong Ruan
Houqiang Xu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Prostate Cancer
Prostate Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12308-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Physician-brief advice for promoting smoking cessation among cancer patients on treatment in low and middle-income countries: a scoping review

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis

MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival

Preimmunization with Listeria-vectored cervical cancer vaccine candidate strains can establish specific T-cell immune memory and prevent tumorigenesis

Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer